Ingen Technologies, Inc. (Pink Sheets:IGNT) is an established medical device manufacturer with an emerging new medical product line targeting the rapidly growing $8 billion global respiratory market. The company recently announced that the pre-recorded interview from Wednesday with CEO, Scott Sand, will be aired again on The Money Channel's American Scene Radio with host Steve Crowley today at 11:24 AM Eastern Daylight Time.
Sand will discuss the new IngenCare product for the $2 trillion drug therapy market expected to be released in August. With the provisional patent filed and production expected in June, the product uses polymer-crystal technology to keep drugs, such as insulin, cool and dry for more than 12 hours while on the go. It is compact, durable and temperature resistant. In addition, Sand will discuss the newest patent on a cannula that will change various colors depending upon flow rate. This new innovative material is embedded into the actual PVC tubing and changes color with various flow rates. "This new product will literally corner the market and complement Ingen's existing Smart Nasal Cannula," stated Scott Sand.
View article: http://respiratorysleepmanagement.com/articles/2010/05/14/medtrade-features-respiratory-sleep-innovations.aspx
"Ingen stands at a key reflex point in its history after having developed a unique solution to a growing problem in the $500 million per year oxygen cannula market," stated Scott Sand, CEO. Ingen recently expanded into 300 VA hospitals in the U.S. through its contract with KGMA, which could quickly ramp up sales to a large patient population, while validating its products in the market.
Ingen recently completed its ISO 13485I, which will help it expand into international markets where it already has a substantial backlog of orders. "Our products can help cut costs for oxygen providers like Lincare Holdings Inc. (LNCR) and Cardinal Health, Inc. (CAH) among other companies, and address a rapidly growing $8 billion global respiratory market facing a COPD epidemic," stated Thomas J. Neavitt, Chief Financial Officer.
Drug-free nasal spray demonstrates effectiveness in blocking viral and bacterial infections